8-K
filed April 30, 2026, 7:59 PM ET
ticker TELA
CIK 0001561921
other material
confidence high
sentiment neutral
materiality 0.80
TELA Bio reports preliminary Q1 revenue of $19.0M; Chairman and three directors to resign, new directors appointed
TELA Bio, Inc.
- Preliminary Q1 2026 revenue approximately $19.0M; unaudited and subject to change after close.
- Chairman Doug Evans and directors Kurt Azarbarzin, Vince Burgess, Federica O'Brien to resign after 2026 annual meeting.
- Board nominates Joseph Capper (CEO of MiMedx) for election as Class I director and future Chairman.
- Board appoints Guido Neels, Guy Nohra, Paul Thomas as new directors effective after 2026 annual meeting.
- Incoming directors and Capper to receive initial equity awards: options for 17,550 shares and RSUs for 11,925 shares.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
TELA Bio, Inc. reported quarter ended March 31, 2026 results: revenue approximately $19.0 million.
- Period
- quarter ended March 31, 2026
- Revenue
- approximately $19.0 million
- Result
- preliminary results
Exact text from the filing
On April 29, 2026, TELA Bio, Inc. (the " Company ") issued a press release announcing its preliminary unaudited revenue for the quarter ended March 31, 2026 of approximately $19.0 million.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kurt Azarbarzin resigned as Director at TELA Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Vince Burgess resigned as Director at TELA Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Guy Nohra was appointed as Director at TELA Bio, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Federica O'Brien resigned as Director at TELA Bio, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul Thomas was appointed as Director at TELA Bio, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Guido Neels was appointed as Director at TELA Bio, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director...
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Doug Evans resigned as Chairman of the Board at TELA Bio, Inc..
- Action
- resigned
- Role
- Chairman of the Board
Exact text from the filing
On April 29, 2026, Doug Evans, Chairman of the Board of Directors (the “ Board ”) of the Company, notified the Company and the Board that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”) and will retire from the Board...
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.